Amplimmune develops immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Its founders have identified key immunomodulatory molecules which are the basis for developing a new class of biological treatments that modulate critical mechanisms in the body's immune system with the aim of bettering the lives of patients. Amplimmune was acquired by Astrazeneca (AZN) in 2013.